298 related articles for article (PubMed ID: 28459463)
21. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
22. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.
Hsu DM; Agarwal S; Benham A; Coarfa C; Trahan DN; Chen Z; Stowers PN; Courtney AN; Lakoma A; Barbieri E; Metelitsa LS; Gunaratne P; Kim ES; Shohet JM
Cancer Res; 2013 Jul; 73(13):4134-46. PubMed ID: 23687340
[TBL] [Abstract][Full Text] [Related]
23. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
24. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; de Preter K; Decock A; Patil N; Abba M; Kopp-Schneider A; Astrahantseff K; Wünschel J; Pfeil S; Ercu M; Künkele A; Hu J; Thole T; Schweizer L; Mechtersheimer G; Carter D; Cheung BB; Popanda O; von Deimling A; Koster J; Versteeg R; Schwab M; Marshall GM; Speleman F; Erb U; Zoeller M; Allgayer H; Simon T; Fischer M; Kulozik AE; Eggert A; Witt O; Schulte JH; Deubzer HE
Oncotarget; 2016 Oct; 7(41):66344-66359. PubMed ID: 27572323
[TBL] [Abstract][Full Text] [Related]
25. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
26. Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.
Mobley BC; Kwon M; Kraemer BR; Hickman FE; Qiao J; Chung DH; Carter BD
PLoS One; 2015; 10(7):e0133897. PubMed ID: 26222553
[TBL] [Abstract][Full Text] [Related]
27. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
28. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
Fielitz K; Althoff K; De Preter K; Nonnekens J; Ohli J; Elges S; Hartmann W; Klöppel G; Knösel T; Schulte M; Klein-Hitpass L; Beisser D; Reis H; Eyking A; Cario E; Schulte JH; Schramm A; Schüller U
Oncotarget; 2016 Nov; 7(46):74415-74426. PubMed ID: 27769070
[TBL] [Abstract][Full Text] [Related]
29. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
[TBL] [Abstract][Full Text] [Related]
30. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma.
Marcus K; Johnson M; Adam RM; O'Reilly MS; Donovan M; Atala A; Freeman MR; Soker S
Neuropathology; 2005 Sep; 25(3):178-87. PubMed ID: 16193833
[TBL] [Abstract][Full Text] [Related]
31. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
32. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
34. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
Cui H; Hu B; Li T; Ma J; Alam G; Gunning WT; Ding HF
Am J Pathol; 2007 Apr; 170(4):1370-8. PubMed ID: 17392175
[TBL] [Abstract][Full Text] [Related]
35. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
36. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche.
Pietras A; Gisselsson D; Ora I; Noguera R; Beckman S; Navarro S; Påhlman S
J Pathol; 2008 Mar; 214(4):482-8. PubMed ID: 18189331
[TBL] [Abstract][Full Text] [Related]
37. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
[TBL] [Abstract][Full Text] [Related]
38. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
39. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
40. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
Weiss WA; Aldape K; Mohapatra G; Feuerstein BG; Bishop JM
EMBO J; 1997 Jun; 16(11):2985-95. PubMed ID: 9214616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]